Cancers & treatments·Regimen libraryFirst line

Nivolumab + ipilimumab (RCC)

Checked 2026-09-09

Untreated advanced clear-cell RCC, IMDC intermediate or poor risk

One cycle

every 21 days × 4 · about 12 weeks in total

21-day cycle × 4 combination, then nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks (about 12 weeks)Intravenous

Components

Drug	Dose	Route	Days	Note
Nivolumab Monoclonal antibody (anti-PD-1)	3 mg/kg	IV	D1
Ipilimumab Monoclonal antibody (anti-CTLA-4)	1 mg/kg	IV	D1

Cycles

4 combination, then nivolumab 240 mg every 2 weeks or 480 mg every 4 weeks

21-day cycle

Emetogenicity

Minimal (<10%)

G-CSF

Not routine

Used in

Renal cell carcinoma

Trials

CheckMate 214

Products

NivolumabIpilimumab

Source

CheckMate 214, NEJM 2018

Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.

Other regimens for these cancers

Everolimus

Advanced progressive NET (RADIANT-3, RADIANT-4); RCC and HR-positive breast cancer after prior therapy

every 28 days

Pembrolizumab + axitinib

Untreated advanced clear-cell RCC, any IMDC risk

every 21 days

Sunitinib 4/2

Advanced clear-cell RCC favourable risk or when immunotherapy is contraindicated; imatinib-resistant GIST; pancreatic NET

every 42 days

All regimens Pembrolizumab + axitinib →